Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Vutrisiran: Use in Patients with Wild-Type ATTR

Standard response letter on the use of vutrisiran in patients with wild-type ATTR.

Patisiran: Pregnancy and Lactation

Standard response letter on patisiran and pregnancy & lactation. This letter contains information on preclinical toxicology studies and the APOLLO, APOLLO-B, and HELIOS-A studies.

Vutrisiran: Use in Patients with Renal Impairment

Standard response letter on vutrisiran and use in patients with renal impairment.

Transition between Patisiran and Vutrisiran

Standard response letter on transitioning between patisiran and vutrisiran therapy.

Vutrisiran: Post-Orthotopic Liver Transplant

Standard response letter on the exclusion of patients with a history of liver transplant from the HELIOS studies of vutrisiran.

Mivelsiran: cAPPricorn-1 Study

Standard response letter on mivelsiran and the phase 2 cAPPricorn-1 study in patients with sporadic or hereditary CAA.

Patisiran: Cardiac Results from the APOLLO Study

Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

Givosiran: Renal Effects

Standard response letter on renal effects observed with the use of givosiran.

Lumasiran: Temperature Cycling and Stability

Standard response letter on the temperature cycling and stability of lumasiran. This letter contains stability data assessed from a batch of lumasiran drug product stored under long term conditions and thermal and cyclic stress.

Vutrisiran: Safety Results from HELIOS-B

Standard response letter on vutrisiran and safety information from the HELIOS-B study.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "Alnylam"

Vutrisiran: Use in Patients with Wild-Type ATTR Standard response letter on the use of vutrisiran in patients with wild-type ATTR.

Patisiran: Pregnancy and Lactation Standard response letter on patisiran and pregnancy & lactation. This letter contains information on preclinical toxicology studies and the APOLLO, APOLLO-B, and HELIOS-A studies.

Vutrisiran: Use in Patients with Renal Impairment Standard response letter on vutrisiran and use in patients with renal impairment.

Transition between Patisiran and Vutrisiran Standard response letter on transitioning between patisiran and vutrisiran therapy.

Vutrisiran: Post-Orthotopic Liver Transplant Standard response letter on the exclusion of patients with a history of liver transplant from the HELIOS studies of vutrisiran.

Mivelsiran: cAPPricorn-1 Study Standard response letter on mivelsiran and the phase 2 cAPPricorn-1 study in patients with sporadic or hereditary CAA.

Patisiran: Cardiac Results from the APOLLO Study Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

Givosiran: Renal Effects Standard response letter on renal effects observed with the use of givosiran.

Lumasiran: Temperature Cycling and Stability Standard response letter on the temperature cycling and stability of lumasiran. This letter contains stability data assessed from a batch of lumasiran drug product stored under long term conditions and thermal and cyclic stress.

Vutrisiran: Safety Results from HELIOS-B Standard response letter on vutrisiran and safety information from the HELIOS-B study.